Equity Overview
Price & Market Data
Price: $6.94
Daily Change: +$0.04 / 0.58%
Range: $6.70 - $7.06
Market Cap: $1,013,128,960
Volume: 899,076
Performance Metrics
1 Week: 14.52%
1 Month: -13.47%
3 Months: -2.66%
6 Months: -14.53%
1 Year: -22.20%
YTD: -11.25%
Company Details
Employees: 93
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.